News – Page 1079 – Endpoints News

SIGN UP

Sean Parker’s cancer institute keeps growing with some “mind blowing” new research projects

8 years ago

FDA follows through with a groundbreaking OK for Yescarta, Gilead's new CAR-T breakthrough

8 years ago

FDA experts shrug off retinopathy concerns, offer (near) unanimous thumbs up for Novo Nordisk's semaglutide

8 years ago

Ablynx sets up a $175M IPO; Blade bags second tranche; Gritstone inks delivery tech deal with Arbutus

8 years ago

Google’s GV and allies double down on Forty Seven with their second $75M round

8 years ago

With $500M-plus, a buyout and two new billion-dollar pacts, upstart Vir is ready to roll on infectious diseases

8 years ago

Eli Lilly is making a $1.8B leap into the mRNA field, targeting next-gen cancer vaccines

8 years ago

Hunting an early FDA OK, Ignyta surges on promising snapshot of lung cancer data

8 years ago

Many questions, few answers in Senate hearing on opaque US drug pricing system

8 years ago

After jumping ship at Eli Lilly, Politico reports Alex Azar may soon land top HHS job

8 years ago

Boston biotech recruits Sanofi’s US cancer research chief; Syndax in-licenses Allergan portfolio

8 years ago

Pfizer, NEA back Cydan II's plans to launch a fresh slate of biotech startups focused on rare genetic diseases

8 years ago

Takeda is beefing up its NASH pipeline with a $470M discovery deal with HemoShear

8 years ago

Cascade of costs could push CAR-T therapy to $1.5M per patient

8 years ago

Orexigen posts a ‘for sale’ sign in the yard as weak Contrave sales raise concerns

8 years ago

J&J is jettisoning two of its promised blockbuster drugs, and it couldn't come at a worse time

8 years ago

Armed with $42.5M, Gemini embraces the Goldilocks strategy in bringing precision med to AMD

8 years ago

Allergan slammed as federal judge invalidates Restasis patents, slaps Mohawk deal

8 years ago

R&D trend #5: The top execs in biotech are riding a boom — but there’s one big step left

8 years ago

Exelixis shares surge on positive liver cancer results; Ramaswamy’s Myovant banks $140M for PhIII

8 years ago

FDA gives Novo Nordisk top grades for its diabetes drug semaglutide, but retinopathy remains key

8 years ago

After getting skunked by rivals, Pfizer touts ‘breakthrough’ cancer drug lorlatinib, heads to the FDA

8 years ago

Racing against Alnylam, Ionis posts positive PhIII ATTR efficacy numbers, but questions linger

8 years ago

EMA counters the academics who criticized the cancer drug approval process

8 years ago

First page Previous page 1076 1077 107810791080 1081 1082 Next page Last page